Obesity Management: Applying Clinical Trial Data to Clinical Care

Despite the recent recognition of obesity a disease, application of this understanding to patient care has been slow. As a result, obese patients often do not receive effective physician-driven weight-loss intervention. The overall objective of this CME program is to increase awareness and understanding of obesity as a disease requiring a concerted therapeutic focus, emphasizing the importance of risk stratification and effective therapeutic interventions, including emerging anti-obesity medications targeting appetite regulation.

Needs assessment: Please see attachment below

Date of original release: May 16, 2014

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Orexigen.

Provided by the American Association of Clinical Endocrinologists.

Program management services provided by AACE Educational Services.

For questions regarding this CME activity, please contact the AACE CME Department through the Contact Us webform or cme@aace.com.

Copyright 2015, AACE. All rights reserved. No part of this enduring material may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission from AACE.

Target Audience

Endocrinologists, primary care providers and other health care providers who treat patients with obesity.

Learning Objectives

  • Recognize the importance of the CNS in appetite regulation and discuss mechanisms by which the CNS regulates appetite.
  • Describe the different approaches to risk stratification of obesity.
  • Discuss the impact of obesity and weight loss on cardiovascular complications and type 2 diabetes.
  • Assess the potential role of weight loss pharmacotherapy in the treatment of obesity and its complications.
  • Compare and contrast the clinical trial data of newly approved weight loss agents and drugs in development for efficacy and safety.
  • Apply knowledge gained from this activity to improve management and outcomes for obese patients.
Additional information
Needs Assessment.pdf0 bytes
Available for MOC Points?: 
Practice Area: 
Course summary
Available credit: 
  • 1.75 AMA
  • 1.75 Attendance
Course opens: 
Course expires: 

Alan J. Garber, MD, PhD, FACE; George Grunberger, MD, FACP, FACE; Jeffrey I. Mechanick, MD, FACP, FACN, FACE, ECNU

Available Credit

  • 1.75 AMA
  • 1.75 Attendance

Accreditation Period

Course opens: 
Course expires: 
Please login or register to take this course.

Required Hardware/software

Users will need a computer with an internet connection, Internet Explorer 8.x or higher, the latest versions of Firefox, Safari, or Chrome, or any other W3C standards compliant browser, Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback and occasionally other additional software may be required such as PowerPoint or Adobe Acrobat Reader.